HIV Core Protein p24

• 

  Subject Areas on Research

  • A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. 
  • A placebo-controlled trial of ranitidine in patients with early human immunodeficiency virus infection. 
  • A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. 
  • Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected patients. 
  • Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action. 
  • CD3+CD8+ cell levels as predictors of transmission in human immunodeficiency virus-infected couples: a report from the heterosexual HIV transmission study. 
  • Cellular fatty acid synthase is required for late stages of HIV-1 replication. 
  • Comparison of Detection Limits of Fourth- and Fifth-Generation Combination HIV Antigen-Antibody, p24 Antigen, and Viral Load Assays on Diverse HIV Isolates. 
  • Comparison of human immunodeficiency virus antigens as stimulants for lymphocyte proliferation assays. 
  • Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences. 
  • Direct and indirect estimates of HIV-1 incidence in a high-prevalence population. 
  • Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. 
  • Enhanced HIV-1 activity in bone marrow can lead to myelopoietic suppression partially contributed by gag p24. 
  • Enhanced Sensitivity for Detection of HIV-1 p24 Antigen by a Novel Nuclease-Linked Fluorescence Oligonucleotide Assay. 
  • Enhanced p24 antigen detection in sera from human immunodeficiency virus-infected children. 
  • Genetically and epidemiologically related "non-syncytium-inducing" isolates of HIV-1 display heterogeneous growth patterns in macrophages. 
  • HIV-1 sensitivity to zidovudine and clinical outcome in children. 
  • HIV-serology and lymphocyte subsets in relation to therapy and clinical development in haemophiliacs. 
  • Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. 
  • Immunodominance and cross-reactivity of B5703-restricted CD8 T lymphocytes from HIV type 1 subtype C-infected Ethiopians. 
  • In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. 
  • Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. 
  • Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) 
  • Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. 
  • Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. 
  • Mononuclear phagocyte accumulation in visceral tissue in HIV encephalitis: evidence for increased monocyte/macrophage trafficking and altered differentiation. 
  • Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. 
  • Nuclear export of late HIV-1 mRNAs occurs via a cellular protein export pathway. 
  • Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon. 
  • Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. 
  • Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. 
  • Renal epithelial cells produce and spread HIV-1 via T-cell contact. 
  • Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. 
  • Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. 
  • Suksdorfin: an anti-HIV principle from Lomatium suksdorfii, its structure-activity correlation with related coumarins, and synergistic effects with anti-AIDS nucleosides. 
  • The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals. 
  • Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. 
  • Ultrastructural evidence of an interaction between Env and Gag proteins during assembly of HIV type 1. 
  • Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. 
  • Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.